Quoin Pharmaceuticals, Ltd. (QNRX) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -253,613.82%, forward earnings yield 74.63%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 32.2 | -0.06 | 66.58 | -1,759.92 | - |
| 2017 | 134.8 | -2.93 | 252.58 | 0.00 | - |
| 2018 | 31.1 | 1.03 | 127.66 | -1,698.72 | - |
| 2019 | -105.9 | 1.00 | 38.46 | 0.00 | - |
| 2020 | -433.5 | 5.42 | -137.47 | 0.00 | - |
| 2021 | -0.7 | 0.00 | 23.22 | 0.00 | - |
| 2022 | -25.7 | 0.26 | 32.52 | 0.00 | 27.10% |
| 2023 | -0.5 | 0.00 | 0.78 | 0.00 | - |
| 2024 | -0.3 | 0.00 | 0.33 | 0.00 | - |
| 2025 | 0.0 | 0.00 | 1.17 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $10,084.00 | $-280K | $15.32M | - |
| 2017 | $5,450.81 | $0.00 | $10.17M | - |
| 2018 | $7,100.73 | $-280K | $15.32M | - |
| 2019 | $-440.29 | $0.00 | $-1.56M | - |
| 2020 | $-88.10 | $0.00 | $-1.76M | - |
| 2021 | $-322.49 | $0.00 | $-8.52M | - |
| 2022 | $-22.97 | $0.00 | $-9.28M | - |
| 2023 | $-9.64 | $0.00 | $-8.69M | - |
| 2024 | $-1,911.50 | $0.00 | $-8.96B | - |
| 2025 | $-14,796.30 | $0.00 | $-15.8B | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-5.07 | $-6.67 – $-3.47 | $13.06M | $9.89M – $16.22M | 1 |
| 2027 | $-4.06 | $-5.33 – $-2.78 | $24.23M | $18.35M – $30.11M | 1 |
| 2028 | $-0.96 | $-1.26 – $-0.65 | $31.11M | $23.56M – $38.66M | 1 |
| 2029 | $4.71 | $3.22 – $6.20 | $53.11M | $40.21M – $66M | 1 |
| 2030 | $6.68 | $4.57 – $8.79 | $71.14M | $53.87M – $88.41M | 1 |
